CD93 and lung carcinoma: More importantly, as a negative or positive regulator of CD93, high sEV-derived miRNA-5193 or C1qA were associated with favorable or unfavorable progression-free survival (PFS) after anti-PD-1 therapy in lung cancer patients (Figure 7G and Table S3).